Navigation Links
Taipan venom no snake oil

Australian snakes' venom could provide the next generation of human therapeutic drugs.

A blood-clotting protein in taipan venom has been identified by Queensland University of Technology PhD researcher Liam St Pierre to rapidly stop excessive bleeding during vascular surgery and major trauma.

The genetic code for the toxin, Factor X (Factor Ten), was identified by PhD researcher Liam St Pierre from QUT's School of Life Sciences who studied the venom of eight of Australia's deadliest land snakes for their therapeutic potential.

His study focussed on the genes in the coastal taipan's venom that are responsible for the pro coagulant or blood clotting agent called Factor X which could stem blood flow in a matter of seconds.

A drug lead based on Factor X is being evaluated for clinical trials by bio pharmaceutical development company QRxPharma.

"Australian snakes literally have a two-pronged attack when they bite their prey," Dr St Pierre said.

"Firstly, venom injection causes massive blood clots instantaneously followed by paralysis as a result of neurotoxins which eventually immobilise and kill the victim."

Dr St Pierre said mammals and snakes naturally produced a small amount of Factor X in their livers.

"Snakes produce a more stable and faster acting form of Factor X in their venom which is the only source of Factor X other than mammalian livers," he said.

"They have developed the ability to deliver massive fatal doses of Factor X to specifically target the systems ofmammals."

Dr St Pierre studied the venom of the inland and coastal taipan, the common brown, the red bellied black, the mulga, the rough-scaled snake, Stephens banded snake and the tiger snake.

"Only the mulga did not have Factor X as it has developed its own unique mechanism of killing."

Dr St Pierre said snake venom was a huge untapped source of potential drug therapies.

His study is the most detailed ever conducted on the genes responsible for Australian snakes' toxins. It is hoped a comprehensive study of all the venom components from Australian snakes may yield further novel components thatcould be targeted as human drugs.


Source:Research Australia

Related biology news :

1. Researchers find first evidence of venom system in extinct mammal
2. Evolution mystery: Spider venom and bacteria share same toxin
3. Stanford snake venom study shows that certain cells may eliminate poison
4. Radioactive scorpion venom for fighting cancer
5. Tarantula venom and chili peppers target same pain sensor
6. Nonvenomous Asian snakes borrow defensive poison from toxic toads
7. Venom doc tracks down snake bioweapons
8. Researchers reveal secrets of flying snakes
Post Your Comments:

(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... 24, 2015  Twist Bioscience, a company focused ... Ph.D., Twist Bioscience chief executive officer, will present ... December 1, 2015 at 3:10 p.m. Eastern Time at The ... --> --> ... Bioscience is on Twitter. Sign up to follow ...
(Date:11/24/2015)... Vancouver, BC (PRWEB) , ... November 24, 2015 ... ... to our customer, OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology ... Creation Technologies’ Texas facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device ...
(Date:11/24/2015)... , Nov. 24, 2015 HemoShear ... on discovering drugs for metabolic disorders, announced today ... to its Board of Directors (BOD). Mr. Watkins ... of Human Genome Sciences (HGS), and also served ... Jim Powers , Chairman and CEO ...
(Date:11/24/2015)... ... November 24, 2015 , ... Whitehouse Laboratories is pleased to announce ... stand-alone facility will be strictly dedicated to basic USP 61, USP 62 and USP ... chance to have complete chemistry and micro testing performed by one supplier. Management ...
Breaking Biology Technology: